Briacell Therapeutics Corp (BCTX) Stock Price, Quote & News

Company Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agree...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 921 1810

Fax: 604 921 1898

Website: briacell.com

Address:

Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

BIGbulls5 Aug. 26 at 6:35 PM

$BCTX this really acting like it wants to go, just doesn't have the volume yet. Might be in on this really early

0 · Reply

rp6577 Aug. 26 at 6:13 PM

$BCTX 🔥

0 · Reply

RafaSantos Aug. 26 at 5:15 PM

$BCTX I’d love to see the Phase 3 results come out on Monday. With good results, we’d see a historic short squeeze.

1 · Reply

yaycapitalism Aug. 26 at 4:18 PM

$BCTX In.

0 · Reply

AliceFireSteam Aug. 26 at 1:05 PM

$BCTX where's data

2 · Reply

Biotechlineup Aug. 25 at 10:27 PM

$BCTX Dear fellow gamblers in Bctx . The science is solid , I have numerous posts in other platforms documenting the mechanism and the high probability of data results that will satisfy the FDA for an accelerated approval. p level .05 and Hazard ratio .78 will easily do it. What does that mean in plain speak. Well let’s say the survival is 9 months in the physicians choice arm , we are looking at 13 months and we got an approval. At 144 pooled deaths that will mathematically and statistically prove a survival benefit. All at a much lower side effects profile. Technically and historically this stock is ripping below the radar. I can talk about momentum indicators and expanding ribbon patterns all day. Here’s the thing, one of the most historically accurate prediction of a short squeeze is the Borrow rate. It screams short squeeze, going from 11 to 58 is very very rare. Means the short supply is tight and expensive. Above is speculation and not financial advice .

1 · Reply

CAN29 Aug. 25 at 8:03 PM

$BCTX

0 · Reply

CAN29 Aug. 25 at 7:54 PM

$BCTX

1 · Reply

AliceFireSteam Aug. 25 at 7:30 PM

$BCTX fee is now at 58.1%

1 · Reply

AliceFireSteam Aug. 25 at 7:08 PM

$BCTX @Biotechlineup yep, squeeze them dry

0 · Reply

BriaCell advances melanoma immunotherapy vaccine candidate Bria-MEL+

Mon, 24 Aug 2026 07:30:00 -0400 - 2 days ago

BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™

2026-08-05T13:46:04.000Z - 21 days ago

BriaCell gets FDA clearance for Bria-PROS+ study in prostate cancer

Wed, 05 Aug 2026 07:30:00 -0400 - 21 days ago

BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer

2026-07-16T13:27:49.000Z - 5 weeks ago

BriaCell (BCTX) Expands Phase 3 Study with New Clinical Site

2026-07-16T11:40:48.000Z - 5 weeks ago

BriaCell announces Odette Cancer Centre joins Bria-IMT trial

Thu, 16 Jul 2026 07:30:00 -0400 - 5 weeks ago

BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer

2026-07-15T13:32:56.000Z - 6 weeks ago

BriaCell (BCTX) Partners with Fujifilm for Cell Therapy Manufacturing

2026-07-15T12:10:22.000Z - 6 weeks ago

BriaCell arranges scalable manufacturing with Fujifilm Biotechnologies

Wed, 15 Jul 2026 07:30:00 -0400 - 6 weeks ago

BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™

Tue, 07 Jul 2026 07:30:00 -0400 - 7 weeks ago

BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™

2026-06-26T10:06:07.000Z - 2 months ago

BriaCell Partners With Uneedle To Support Scalable Microneedle Delivery Of Bria-IMT

2026-06-25T13:25:58.000Z - 2 months ago

BriaCell (BCTX) Partners with Uneedle for Microneedle Technology Development

2026-06-25T11:45:30.000Z - 2 months ago

BriaCell enters MoU with Uneedle for microneedle technology

Thu, 25 Jun 2026 07:30:00 -0400 - 2 months ago

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™

Tue, 02 Jun 2026 16:05:00 -0400 - 3 months ago

BriaCell Therapeutics Announces Closing of Offering

Mon, 01 Jun 2026 07:30:00 -0400 - 3 months ago

BriaCell Presents Positive Clinical Data at ASCO 2026

Sun, 31 May 2026 19:59:00 -0400 - 3 months ago

BriaCell Therapeutics Announces Pricing of Offering

2026-05-26T14:43:01.000Z - 3 months ago

BriaCell (BCTX) Receives Positive Update from Data Safety Monitoring Board

2026-05-26T13:05:39.000Z - 3 months ago

BriaCell receives recommendation for DSMB for Phase 3 Bria-ABC study

Tue, 26 May 2026 07:30:00 -0400 - 3 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

2026-05-22T13:27:19.000Z - 3 months ago

BriaCell (BCTX) Unveils Key Clinical Data at ASCO Annual Meeting 2026

2026-05-22T11:49:02.000Z - 3 months ago

BriaCell announces data from Bria-IMT at ASCO 2026

Fri, 22 May 2026 07:30:00 -0400 - 3 months ago

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026

Fri, 15 May 2026 07:30:00 -0400 - 3 months ago

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

2026-05-14T15:31:53.000Z - 3 months ago

BriaCell (BCTX) Completes Manufacturing for New Prostate Cancer Treatment

Thu, 14 May 2026 07:30:00 -0400 - 3 months ago

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer

2026-05-13T16:39:28.000Z - 3 months ago

BriaCell (BCTX) Expands Clinical Trial Network for Advanced Breast Cancer Treatment

2026-05-13T14:41:55.000Z - 3 months ago

BriaCell adds Penn Medicine as Phase 3 breast cancer study site

Wed, 13 May 2026 07:30:00 -0400 - 3 months ago

BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

Tue, 12 May 2026 07:30:00 -0400 - 3 months ago

BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients

Thu, 07 May 2026 07:30:00 -0400 - 3 months ago

BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

2026-05-07T04:03:56.000Z - 3 months ago

BriaCell receives FDA clearance to initiate Bria-BRES+ trial

Wed, 06 May 2026 07:30:00 -0400 - 4 months ago

BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer

Mon, 27 Apr 2026 07:30:00 -0400 - 4 months ago

BriaCell Announces Six Clinical Data Presentations at ASCO 2026

2026-04-21T13:28:43.000Z - 4 months ago

BriaCell (BCTX) Showcases Promising Data at AACR Annual Meeting

2026-04-21T11:54:23.000Z - 4 months ago

BriaCell presents anti-cancer activity of Bria-OTS

Tue, 21 Apr 2026 07:30:00 -0400 - 4 months ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

2026-04-20T13:32:04.000Z - 4 months ago

BriaCell (BCTX) Showcases Positive Clinical Data at AACR Annual Meeting

2026-04-20T11:41:56.000Z - 4 months ago

BriaCell presents Phase 3 quality of life, Phase 2 biomarker data at AACR

Mon, 20 Apr 2026 07:30:00 -0400 - 4 months ago

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

Tue, 31 Mar 2026 16:05:00 -0400 - 5 months ago

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

2026-03-18T13:30:56.000Z - 5 months ago

BriaCell (BCTX) to Reveal Key Findings at 2026 AACR Annual Meeting

2026-03-18T11:42:55.000Z - 5 months ago

BriaCell to present four posters at the 2026 AACR

Wed, 18 Mar 2026 07:30:00 -0400 - 5 months ago

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

Tue, 10 Mar 2026 07:30:00 -0400 - 6 months ago

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

Thu, 05 Mar 2026 16:04:00 -0500 - 6 months ago

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

2026-02-18T22:51:30.000Z - 6 months ago

BriaCell (BCTX) Expands Biologic Cancer Treatments Through New Agreement

2026-02-18T22:35:25.000Z - 6 months ago

BriaPro to purchase BriaCell’s license to develop, commercialize sCD80

Wed, 18 Feb 2026 17:30:00 -0500 - 6 months ago

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

2026-02-17T12:40:59.000Z - 6 months ago

BriaCell receives positive recommendation from DSMB for Phase 3 Bria-ABC study

2026-01-28T12:40:40.000Z - 7 months ago

BriaCell says patient images show regression, resolution of metastsized tumors

Jan 28, 2026, 7:30 AM EST - 7 months ago

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

2026-01-27T12:41:04.000Z - 7 months ago

BriaCell extends 18-47 month survival in Phase 2 metastatic breast cancer

Jan 27, 2026, 7:30 AM EST - 7 months ago

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

Jan 15, 2026, 4:05 PM EST - 7 months ago

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

Jan 13, 2026, 9:00 PM EST - 8 months ago

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

2026-01-13T14:41:11.000Z - 8 months ago

BriaCell Therapeutics trading resumes

2026-01-13T14:35:29.000Z - 8 months ago

BriaCell Therapeutics trading halted, volatility trading pause

2026-01-13T12:35:49.000Z - 8 months ago

BriaCell reports sustained complete resolution of lung metastasis in Bria-OTS

Jan 13, 2026, 7:30 AM EST - 8 months ago

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

Dec 18, 2025, 7:30 AM EST - 8 months ago

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

Dec 10, 2025, 7:30 AM EST - 9 months ago

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

Dec 9, 2025, 7:30 AM EST - 9 months ago

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

Dec 2, 2025, 7:30 AM EST - 9 months ago

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

Nov 25, 2025, 7:30 AM EST - 9 months ago

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

Nov 20, 2025, 7:30 AM EST - 9 months ago

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

Nov 18, 2025, 7:30 AM EST - 10 months ago

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Nov 7, 2025, 7:30 AM EST - 10 months ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

Nov 4, 2025, 7:30 AM EST - 10 months ago

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

Oct 21, 2025, 7:50 AM EDT - 11 months ago

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

Oct 21, 2025, 7:30 AM EDT - 11 months ago

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

Oct 20, 2025, 7:30 AM EDT - 11 months ago

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

Oct 13, 2025, 7:30 AM EDT - 11 months ago

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

Oct 3, 2025, 7:30 AM EDT - 11 months ago

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

Aug 26, 2025, 7:30 AM EDT - 1 year ago

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Aug 25, 2025, 7:30 AM EDT - 1 year ago

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

Aug 21, 2025, 12:00 PM EDT - 1 year ago

BriaCell Announces Proposed Effective Date of Share Consolidation

Aug 13, 2025, 7:30 AM EDT - 1 year ago

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

Jul 31, 2025, 7:30 AM EDT - 1 year ago

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

Jul 30, 2025, 7:30 AM EDT - 1 year ago

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

BIGbulls5 Aug. 26 at 6:35 PM

$BCTX this really acting like it wants to go, just doesn't have the volume yet. Might be in on this really early

0 · Reply

rp6577 Aug. 26 at 6:13 PM

$BCTX 🔥

0 · Reply

RafaSantos Aug. 26 at 5:15 PM

$BCTX I’d love to see the Phase 3 results come out on Monday. With good results, we’d see a historic short squeeze.

1 · Reply

yaycapitalism Aug. 26 at 4:18 PM

$BCTX In.

0 · Reply

AliceFireSteam Aug. 26 at 1:05 PM

$BCTX where's data

2 · Reply

Biotechlineup Aug. 25 at 10:27 PM

1 · Reply

CAN29 Aug. 25 at 8:03 PM

$BCTX

0 · Reply

CAN29 Aug. 25 at 7:54 PM

$BCTX

1 · Reply

AliceFireSteam Aug. 25 at 7:30 PM

$BCTX fee is now at 58.1%

1 · Reply

AliceFireSteam Aug. 25 at 7:08 PM

$BCTX @Biotechlineup yep, squeeze them dry

0 · Reply

Biotechlineup Aug. 25 at 6:09 PM

$BCTX Spike in borrow fee ? Checked fintel to understand what happened, lets map the data data points to Fintel's standard layout columns << Date] | [Open] | [Low] | [High] | [Close].2026-08-24 (Yesterday) The fee opened at 9.92%, hit a high of 10.56%, and closed the day at 10.49%. This matches the steady baseline at the morning press release.2026-08-25 (Today), The fee opened this morning exactly where it closed yesterday (10.49%). The intraday low was 10.49%, but it spiked to an intraday High of 37.69%! Anyone else confirm this with real time data?? Borrow fee spike is probably one of the most reliable indicators of a short squeeze if real and sustainable.

2 · Reply

ZacksResearch Aug. 25 at 4:23 PM

$BCTX is up 17.5% 🚀 BriaCell’s personalized, off-the-shelf Bria-MEL+ recently passed a key genetic engineering milestone, with development activities now underway to support production for potential clinical use. Find more on BCTX here👉https://www.zacks.com/stock/quote/BCTX?cid=sm-stocktwits-0-quote_overview-oc-39373&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_39373

0 · Reply